Due to the limitations of the Sanger method, the molecular defect could only be defined in approximately 30% of cases. In the remaining 70% of patients, the genetic cause remained unidentified, highlighting the need for further evaluation using an extended NGS panel targeting genes associated with inherited thrombocytopenias.
Ferrari et al. (Mon,) studied this question.